TG8-260 is a second-generation EP2 antagonist developed to mitigate pathology in inflammatory-driven central and peripheral nervous system disorders. In a rat model, TG8-260 reduced neuroinflammation and gliosis in the hippocampal region following pilocarpine-induced status epilepticus. Pharmacokinetic data for TG8-260 reveal a plasma half-life of 2.14 hours and an oral bioavailability of 77.3%. Furthermore, TG8-260 acts as a potent inhibitor of CYP450 and demonstrates antagonistic activity by inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglial cells, making it suitable for research on anti-inflammatory pathways in animal models of peripheral inflammatory diseases.